Technology-enabled service for managing late-stage cancer
Addressing a poorly served stage of the cancer patient journey
Many technologies support cancer screening, diagnosis, and early-stage treatment, but only AIQ enables optimization of late-stage care
For late-stage cancer, each individual lesion responds differently to therapy
TRAQinform IQ Technology
TRAQinform IQ is a software medical device that provides novel information about quantification of change in regions of interest over time. Oncologists/clinicians use this technology to more precisely adjust therapies and optimize clinical outcomes.
TRAQinform IQ Report
Understanding Treatment Response Heterogeneity
Intra-patient heterogeneity is nearly universal in cancer.4. Having as few as 9% of lesions not responding to therapy can result in significantly worse outcomes.5,6
SUVhetero is an imaging metric of intra-patient heterogeneity. Change in SUVhetero was the most significant predictor of time to PSA progression (hazard ratio [HR], 3.88; 95% CI, 1.24 to 12.1) and time to treatment discontinuation (HR, 4.21; 95% CI, 1.28 to 13.8) in a study of men with progressive metastatic castration-resistant prostate cancer (mCRPC).3
Comparison to Standard of Care
Easy integration into existing workflows
 TRAQinform IQ uses serial radiographic images (e.g., PET, CT) |
 |
 Images are uploaded via the cloud to AIQ solutions (HIPAA compliant) |
|
 Software that provides novel, quantitative and spatial information about each region of interest |
|
 A comprehensive report is generated and delivered to the oncologist |
|
 Oncologists can use the information to tailor treatment regimens and optimize outcomes |
Interested in using TRAQinform IQ at your hospital?
1: Seyfried TN, Huysentruyt LC. On the Origin of Cancer Metastasis. Crit Rev Oncog. 2013;18(1-2).
2: Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff R. Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1302-1312.
3: Lokre, O., Perk, T.G., Weisman, A.J. et al. Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome. Eur J Nucl Med Mol Imaging. 2024.
4: Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-37.
5: Harmon SA, Perk T, Lin C, et al. Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone. J Clin Oncol. 2017;35(24):2829-2837, including unpublished supplemental data analysis.
6: Kyriakopoulos CE, Heath EI, Ferrari A, et al. Exploring Spatial-Temporal Changes in 18F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide. J Clin Oncol. 2020;38(31):3662-3671.